LHC Group, Inc. (Nasdaq: LHCG)

The firm is investigating a derivative case against LHC Group, Inc. (Nasdaq: LHCG) on behalf of continuous shareholders of the stock since January 1, 2008 or earlier. LHC is one of the largest home health and hospice care companies in the U.S. It is a Delaware corporation with its principal place of business in Louisiana. On Sept. 29, 2011, the Company agreed to pay the U.S. $65 million to settle a qui tam action filed in 2007 regarding allegations that it committed Medicare fraud by providing medically unnecessary patient care, targeting a certain number of home therapy visits to trigger bonus payments.

The company has recently been investigated by the United States Senate Finance Committee and the SEC, which found documentary evidence from top executives that the Company encouraged its therapists to target the most profitable number of therapy visits even where patient need did not justify it.

The firm would like to bring a derivative action on behalf of LHC Group, Inc. against certain of its current and former directors and officers for breaches of fiduciary duties in connection with the fraud, ultimately costing the company millions in investigatory, fine and settlement expenses.

If you are a current shareholder and would like to discuss your options of exercising your rights as a shareholder, which includes ensuring that the board of directors will act in the best interest of the shareholders, please contact us.

Please submit the following information so we can determine if you qualify for the suit. If you don't know all the specific details, partial information is also acceptable.